title: Interleukin-23 in the pathogenesis and treatment of psoriasis.
abstract: In the past three decades, major advances have been made in understanding the pathogenesis of psoriasis. The currently accepted theory is that T-cell mediated immune dysregulation triggers keratinocyte hyperproliferation in psoriasis. Recent research indicates that the Th17/interleukin (IL)-23 pathway plays a prominent role in the amplification phase of psoriasis. The discovery of the Th17/ IL-23 pathway provides targets for new drug development. This review focuses on the role of IL-23 in psoriasis pathogenesis and the current therapies targeting IL-23 that are in clinical trials.
authors: Center for Clinical Studies, Houston, TX, USA.
authors: Ramya
authors: R
authors: Kollipara
authors: Center for Clinical Studies, Houston, TX, USA.
authors: Christopher
authors: C
authors: Downing
authors: Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA.
authors: Rachel
authors: R
authors: Gordon
authors: Center for Clinical Studies, Houston, TX, USA.
authors: Stephen
authors: S
authors: Tyring
mesh_terms: D000818:Animals; D049109:Cell Proliferation; D015195:Drug Design; D006801:Humans; D053759:Interleukin-23 / Q000276:immunology*; D015603:Keratinocytes / Q000166:cytology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D058504:Th17 Cells / Q000276:immunology
chemical_list: D053759:Interleukin-23